Detalles de la búsqueda
1.
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
BMC Cancer
; 22(1): 851, 2022 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35927710
2.
Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study.
Support Care Cancer
; 30(9): 7249-7260, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589878
3.
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.
Ann Surg
; 274(2): 383-389, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33843797
4.
Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.
Future Oncol
; 16(11): 619-629, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32125175
5.
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).
Future Oncol
; 15(19): 2203-2209, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31023100
6.
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
J Transl Med
; 14: 95, 2016 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27095081
7.
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
J Transl Med
; 14(1): 232, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27484791
8.
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.
Cancer Immunol Immunother
; 64(3): 381-8, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25548092
9.
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.
Cancer Immunol Immunother
; 63(9): 959-67, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24878889
10.
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Cancer Immunol Immunother
; 63(10): 1023-36, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24947180
11.
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
Eur J Cancer
; 200: 113601, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38340383
12.
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
Clin Cancer Res
; 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38739109
13.
Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.
Mol Ther
; 20(5): 1063-74, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22371843
14.
Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.
Crit Rev Oncol Hematol
; 183: 103919, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36736511
15.
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
Eur Urol Open Sci
; 55: 15-22, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37693729
16.
An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial.
JMIR Res Protoc
; 12: e49252, 2023 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37819691
17.
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
J Immunother Cancer
; 11(7)2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37479483
18.
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.
Cancer Immunol Immunother
; 61(7): 1033-43, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22159452
19.
Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
Cancer Invest
; 30(10): 712-20, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23043499
20.
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.
Eur Urol Open Sci
; 35: 54-58, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35024632